Skip to content

Quantitative Fecal Immunochemical Test for Detection of Colorectal Cancer and Precancerous Lesions in Sohag

Role of Quantitative Fecal Immunochemical Test as a Diagnostic Tool in Evaluation of Site and Type of Colorectal Cancer and Precancerous Lesions in Sohag Government

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07410546
Enrollment
150
Registered
2026-02-13
Start date
2026-02-01
Completion date
2026-08-01
Last updated
2026-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Adenoma, Colorectal Cancer, Sessile Serrated Lesion

Brief summary

Colorectal cancer is a major cause of cancer-related morbidity and mortality worldwide, and early detection significantly improves patient outcomes. The fecal immunochemical test (FIT) is a non-invasive stool-based test used for detection of colorectal cancer; however, its diagnostic performance varies according to lesion type and anatomical location. This prospective observational cohort study aims to evaluate the diagnostic accuracy of quantitative fecal immunochemical testing (qFIT) in detecting colorectal cancer and precancerous lesions, including advanced adenomas and sessile serrated lesions, in adults undergoing colonoscopy in Sohag Government. The study will assess the sensitivity, specificity, and optimal cutoff values of qFIT according to lesion type, location, and histopathological characteristics.

Detailed description

This is a prospective observational cohort study conducted at a tertiary care endoscopy unit in Sohag Government. Adult patients aged 40 to 75 years who are referred for diagnostic or screening colonoscopy will be invited to participate. All eligible participants will provide a stool sample for quantitative fecal immunochemical testing (qFIT) prior to bowel preparation. Fecal hemoglobin concentration will be measured using a quantitative FIT assay and expressed as micrograms of hemoglobin per gram of stool. All participants will subsequently undergo colonoscopy as part of routine clinical care. Colonoscopic findings will be recorded, including lesion presence, anatomical location (proximal colon, distal colon, or rectum), size, and morphology. Biopsy or polypectomy specimens will be examined histopathologically to confirm colorectal cancer, advanced adenomas, or sessile serrated lesions. The diagnostic performance of qFIT will be evaluated by calculating sensitivity, specificity, positive predictive value, and negative predictive value for detection of colorectal cancer and precancerous lesions. Receiver operating characteristic (ROC) curve analysis will be used to determine optimal qFIT cutoff values according to lesion type and anatomical location. Associations between qFIT levels and lesion characteristics will also be analyzed.

Interventions

None listed

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* Adults aged 40 to 75 years * Individuals undergoing screening or diagnostic colonoscopy * Participants able to provide informed consent

Exclusion criteria

* Age below 40 years or above 75 years * History of colorectal surgery * Inflammatory bowel disease * Inadequate bowel preparation * Refusal to participate

Design outcomes

Primary

MeasureTime frameDescription
Diagnostic Accuracy of Quantitative Fecal Immunochemical TestUp to 1 dayAssessment of the diagnostic accuracy of quantitative fecal immunochemical testing (qFIT) for detection of colorectal cancer and precancerous colorectal lesions, expressed as sensitivity, specificity, positive predictive value, and negative predictive value, using colonoscopy and histopathology as the reference standard.

Secondary

MeasureTime frameDescription
Diagnostic Performance of qFIT by Lesion TypeUp to 1 dayComparison of quantitative fecal immunochemical test performance for detection of colorectal cancer, advanced adenomas, and sessile serrated lesions.
Diagnostic Performance of qFIT by Lesion LocationUp to 1 dayEvaluation of quantitative fecal immunochemical test performance according to anatomical location of colorectal lesions, including proximal colon, distal colon, and rectum.
Correlation Between qFIT Level and Lesion CharacteristicsUp to 1 dayAssessment of the relationship between fecal hemoglobin concentration and lesion size, morphology, and histopathological grade.

Contacts

CONTACTPierre Isac Ibrahim
bebareshak@med.sohag.edu.eg+201273119744
PRINCIPAL_INVESTIGATORUsama Abdelaal, MD

Faculty of Medicine, Sohag University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026